STOCK GOODIES PLAYS OF THE WEEK

[1~Eye~Jack!!]

~ RGBP = My bet is we arRre~Dayyum..close..to..FDA~Approval,, I think what probably happened is that Dr. Thomas Ichim got sick,,and still worked on getting things to the FDA,, it just took a couple weeks,, as he is sick with something serious,, and might have started some kinda Treatment...

Dr. Thomas Ichim = Thank-you for ALL the hard work you have done for RGBP & Cancer Research!!!
http://ih.advfn.com/p.php?pid=nmona&article=69187117

October 30, 2015

Dear Dr. Koos

Please consider this letter my formal resignation from position of Chief Scientific Officer and Board Member of Regen Biopharma due to health reasons.
On October 30, 2015 Thomas Ichim resigned from his position as Chief Scientific Officer, Director of Research and member of the Board of Directors of Regen Biopharma, Inc. ( “Regen”) due to health reasons.

On October 30, 2015 Dr. Harry M. Lander, Ph.D., M.B.A., age 50, was appointed to the position of Chief Scientific Officer of Regen effective October 30, 2015.

Dr.Lander received an MBA in Finance from The New York University Stern School of Business in New York City in 1991 and a Ph.D. in Biochemistry from the Cornell University Graduate School of Medical Sciences. Dr. Lander has also earned a Bachelor of Science in Biochemistry and a Bachelor of Science in Chemistry from State University of New York at Stony Brook. Prior to accepting the office of President at Regen, Dr. Lander served as Research Chief-Administration at Sidra Medical and Research Center, a new women’s and children’s hospital (expected to open in 2018) established to provide care to Qatari and Middle East residents based on the North American academic medical center model. His duties at the Medical and Research Center included assisting in the development of financial, operational , and compliance infrastructures for the Center as well as assisting in developing the Center’s scientific strategy through a 5 year strategic plan.

On November 2, 2015 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with Thomas Ichim pursuant to the following terms and conditions.

Thomas Ichim shall render to Regen consulting services as set forth in a Consulting Services Letter (the “Supporting Documents”) and agrees to being referred to during the term of this Agreement under the title “Senior Research Consultant Thomas Ichim to Regen BioPharma, Inc.”. A Consulting Services Letter shall mean a document that describes Thomas Ichim’s consulting services and pricing for such services. In the event of a conflict between the terms contained in the Supporting Documents and this Agreement, the terms of this Agreement shall control, unless specifically agreed upon to the contrary in the Supporting Documents. Any and all Supporting Documents shall contain a clear and concise description of the services to be performed by the Thomas Ichim and an estimation of the cost to Regen for such services as well as the period of time required by the Thomas Ichim to complete such services. The Supporting Documents when executed by Thomas Ichim and Regen shall be incorporated into and made a part of this Agreement. Regen shall be under no obligation to execute any Consulting Services Letter. No Consulting Services Letter shall be binding upon Regen unless executed by Regen. The Term of the Agreement commences on November 2, 2015 and expires on November 2, 2016.